{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:31:51Z","timestamp":1793971911734,"version":"4.8.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.xcrm.2021.100392","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T10:41:23Z","timestamp":1630665683000},"page":"100392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Molecular predictors of response to pembrolizumab in thymic carcinoma"],"prefix":"10.1016","volume":"2","author":[{"given":"Yongfeng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Bhuvaneshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2021.100392_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1067\/mtc.2003.133","article-title":"Aggressive multimodality treatment of invasive thymic carcinoma","volume":"125","author":"Greene","year":"2003","journal-title":"J.\u00a0Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.xcrm.2021.100392_bib2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.xcrm.2021.100392_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.xcrm.2021.100392_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2021.100392_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2021.100392_bib6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/carcin\/bgx094","article-title":"The genomic and epigenomic landscape in thymic carcinoma","volume":"38","author":"Saito","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xcrm.2021.100392_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.xcrm.2021.100392_bib10","doi-asserted-by":"crossref","first-page":"E535","DOI":"10.21037\/jtd.2016.06.32","article-title":"Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases","volume":"8","author":"Yang","year":"2016","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.xcrm.2021.100392_bib11","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2016.07.018","article-title":"Response to Pembrolizumab in a Patient with Relapsing Thymoma","volume":"11","author":"Zander","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib12","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib15","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2021.100392_bib16","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2021.100392_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2020.07.018","article-title":"Downregulation of CYLD promotes IFN-\u03b3 mediated PD-L1 expression in thymic epithelial tumors","volume":"147","author":"Umemura","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4161\/cbt.11.7.14948","article-title":"Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies","volume":"11","author":"Bertino","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.xcrm.2021.100392_bib19","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib20","first-page":"1083","article-title":"Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy","volume":"56","author":"Chen","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib21","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/sj.leu.2402570","article-title":"Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T\u00a0cell leukemia (ATL)","volume":"16","author":"Harasawa","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2021.100392_bib22","doi-asserted-by":"crossref","first-page":"LB-A18","DOI":"10.1158\/1535-7163.TARG-19-LB-A18","article-title":"The frequent tumor deletion of MTAP is a newly recognized potent immune checkpoint that is effectively reversed by a human methylthioadenosine degrading drug candidate","volume":"18","author":"Gjuka","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2021.100392_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.immuni.2017.07.020","article-title":"The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression","volume":"47","author":"Pan","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2021.100392_bib24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s40425-019-0737-3","article-title":"Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers","volume":"7","author":"Wu","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib25","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1158\/0008-5472.CAN-04-4223","article-title":"Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner","volume":"65","author":"Tsuchihara","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib26","doi-asserted-by":"crossref","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2021.100392_bib27","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib28","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2021.100392_bib29","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2021.100392_bib30","doi-asserted-by":"crossref","first-page":"E1340","DOI":"10.3390\/ijms19051340","article-title":"Mechanisms of Intrinsic Tumor Resistance to Immunotherapy","volume":"19","author":"Rieth","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2021.100392_bib31","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100392_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.5384","article-title":"Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development","volume":"250","author":"Figueiredo","year":"2020","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.xcrm.2021.100392_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib35","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2021.100392_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2021.100392_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00030","article-title":"Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1\/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis","volume":"1","author":"Khunger","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2021.100392_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/0008-5472.CAN-17-1615","article-title":"Interferon-\u03b3 Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4","volume":"78","author":"Mo","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib40","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2021.100392_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2021.100392_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2021.100392_bib43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2021.100392_bib44","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib45","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.21037\/jtd.2018.11.102","article-title":"Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors","volume":"11","author":"Berland","year":"2019","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.xcrm.2021.100392_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.biocel.2015.01.001","article-title":"BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells","volume":"60","author":"Pan","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.xcrm.2021.100392_bib47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41419-018-0500-6","article-title":"BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma","volume":"9","author":"Sime","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2021.100392_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2021.100392_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1535-7163.MCT-19-0356","article-title":"Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition","volume":"19","author":"Okonska","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2021.100392_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2021.100392_bib51","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-16-0072","article-title":"The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma","volume":"4","author":"Ascierto","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib52","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100392_bib53","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2013.49.2157","article-title":"Prediction of response to anticancer immunotherapy using gene signatures","volume":"31","author":"Wang","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib54","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2021.100392_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0489-5","article-title":"Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors","volume":"7","author":"Conroy","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2217\/imt-2019-0177","article-title":"Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS \u226550%) metastatic NSCLC at US oncology practices","volume":"11","author":"Velcheti","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.xcrm.2021.100392_bib57","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41416-018-0220-9","article-title":"Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","volume":"119","author":"Fumet","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2021.100392_bib59","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.3390\/cancers11020201","article-title":"The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer","volume":"11","author":"Kaderbha\u00ef","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2021.100392_bib60","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"issue":"15_suppl","key":"10.1016\/j.xcrm.2021.100392_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3001","article-title":"Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature","volume":"33","author":"Ribas","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2021.100392_bib62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2021.100392_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2021.100392_bib64","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41379-020-0498-z","article-title":"Multiparametric in\u00a0situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment","volume":"33","author":"Patel","year":"2020","journal-title":"Mod. Pathol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379121002500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379121002500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:48:04Z","timestamp":1762987684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379121002500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2666379121002500"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100392","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular predictors of response to pembrolizumab in thymic carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100392"}}